High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

Search

Bacteriophage

Bacteriophages (phages) have been minimally used in emergency clinical applications for skin and soft tissue infections and disseminated bacterial infections, but not to-date as an aerosol strategy against pulmonary mycobacteria. One limitation in the field preventing these advancements is the availability of a reproducible preclinical model of aerosol phage delivery that can be leveraged for efficacy testing. Importantly, our preliminary proof-of-concept results1 (read the paper) suggest that aerosol delivery of phage to mice can significantly reduce bacterial burden after challenge with M.tb. 

Our lab is actively collaborating to develop reproducible aerosol models of delivery and answer longstanding biological questions about phage treatment in vivo. This includes basic host immunological outcomes of repeated phage treatment, route of delivery and pharmacodynamics/kinetics. This work is done extensively in partnership with the Hatfull Lab at the University of Pittsburg, and has been supported through NIAID grant funding.

  1. Carrigy NB, Larsen SE, Reese V, Pecor T, Harrison M, Kuehl PJ, Hatfull GF, Sauvageau D, Baldwin SL, Finlay WH, Coler RN, Vehring R. Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29. Antimicrob Agents Chemother. 2019 Sep 16;63(12):e00871-19. doi: 10.1128/AAC.00871-19. Epub ahead of print. PMID: 31527037; PMCID: PMC6879268.

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.